Newswise — ORLANDO, Fla. — The American Association for Cancer Research Annual Meeting continues to be a showcase for the most cutting edge science in cancer, and this year’s meeting, held here April 2-6, will include an increased focus on clinical trials that will impact patient care.
Daniel D. Von Hoff, M.D., physician-in-chief and distinguished professor at the Translational Genomics Research Institute (TGen), professor of medicine at the Mayo Clinic, and chief scientific officer at Scottsdale Healthcare and U.S. Oncology Research, will host a press conference on Saturday, April 2 at 10:00 a.m. ET in room W313 of the Orange County Convention Center.
“Scientists in the drug development arena are rethinking how trials are conducted in the wake of so much new knowledge about biomarkers and genetics,” he said. “These results will show how it is playing out in both treatment and prevention of lung cancer, breast cancer and other hard to treat malignancies.”
The following research will be presented during this press conference:
• New Inhibitor Prevented Lesions, Reduced Tumor Size in Basal Cell Cancer• BATTLE Researchers Identify New Biomarkers for EGFR Inhibition• Combining MEK and PI3K Inhibitors Appears Encouraging in a Safety Study with Early Signs of Anti-tumor Activity • Target for Lung Cancer Chemoprevention Identified• DNA of 50 Breast Cancer Patients Decoded
Reporters who cannot attend in person can participate by using the following information:
• U.S. & Canada: (888) 647-7462• International: (201) 604-0169• Access Code: 244078
Press registration for the AACR 102nd Annual Meeting 2011 is free to qualified journalists and public information officers: http://www.aacr.org/PressRegistration
Follow the AACR on Twitter: @aacr #aacr Follow the AACR on Facebook: http://www.facebook.com/aacr.org
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world’s oldest and largest professional organization dedicated to advancing cancer research. The membership includes 32,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowships and career development awards. The AACR Annual Meeting attracts more than 18,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. Including Cancer Discovery, the AACR publishes seven major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. AACR journals represented 20 percent of the market share of total citations in 2009. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists.
RSS